Invivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 15th total of 3,670,000 shares. Based on an average daily trading volume, of 958,500 shares, the short-interest ratio is currently 4.2 days. Currently, 5.3% of the company’s shares are sold short.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 160,400 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. The trade was a 3.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 816,466 shares of company stock valued at $423,214 in the last three months. Company insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. XTX Topco Ltd raised its stake in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in Invivyd during the 3rd quarter worth approximately $27,000. Marshall Wace LLP grew its position in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares during the last quarter. State Street Corp grew its position in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on IVVD. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. HC Wainwright reduced their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Friday, January 10th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Down 7.5 %

NASDAQ IVVD opened at $0.41 on Tuesday. The firm has a market cap of $48.61 million, a PE ratio of -0.21 and a beta of 0.64. The company has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.88. Invivyd has a 52 week low of $0.38 and a 52 week high of $5.20.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.